obsessive-compulsive disorder obssessief compulsieve stoornis
Conditions
Interventions
Patients will be randomly assigned to
metacognitive therapy or exposure and responsprevention. The interventions will be offered at the Anxiety Disorders Department of PsyQ (Rotterdam and Spijkenisse)
(1) metacognitive beliefs about the meaning and consequences of intrusive thoughts and
feelings, and (2) beliefs about the necessity of performing rituals and the negative consequences of failing to d
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria are: 1) primary diagnosis of OCD 2) age 18-65.
Exclusion criteria
Exclusion criteria: Patients are only excluded if they currently: 1) meet DSM-IV-TR criteria for severe major depressive disorder that requires immediate treatment, psychotic disorder, or bipolar disorder, 2) have substance abuse requiring specialist treatment, or 3) have a change in psychiatric medication type or dose in the six weeks before assessment or during treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment outcome will be evaluated by means of the Dutch versions of both a standardized self-report scale (Padua Inventory; Burns et al., 1996) and a semi-structured interview (Yale-Brown Obsessive Compulsive Scale [Y-BOCS]; Goodman et al., 1989) for measuring the core symptoms of OCD (primary outcomes). Additionally, we will do a SCID-I screening. To study changes in both belief domains that have been proposed to be important in the etiology of OCD and metacognitive beliefs about the meaning, significance, and danger of intrusive thoughts, the Obsessive Beliefs Questionnaire-44 (OBQ-44; OCCWG, 2005), the Thought Fusion Instrument (TFI; Wells et al., 2001) and the Beliefs About Rituals Inventory (BARI; Adrian Wells & Kirsten McNicol, 2012) will be employed. | — |
Secondary
| Measure | Time frame |
|---|---|
| In addition of the primary study parameters, questionnaires of general psychopathology (Symptom Checklist [SCL-90]; Derogatis, 1983), depression (Beck Depression Inventory, 2nd version [BDI-II]; Beck et al., 1996), and quality of life (WHOQOL-Bref; WHO, 2004) will be administered to assess comorbid symptoms and degree of perceived well-being (secondary outcomes). At entry also three additional measurements will be employed in order to describe the participants characteristics at baseline (intolerance of uncertainty scale [IUS]; Freeston, Rheaume, Letarte, Dugas, & Ladouceur, 1994; NEO Five Factor Index [NEO-FFI]; Costa & mcCrae, 1992; Anxiety Sensitivity Index [ASI]; Reiss, Peterson, Gursky, & McNally, 1986). Additionally, on both follow-up assessments, participants will be called by a member of the research team, who will ask them to provide responses for the Treatment Change Recording Form (TCRF; Tolin et al., 2004), which will be used to assess the initiation, termination, or change of any form of therapy, hospital services, support group, self-help program, or medication utilized by the participant since posttreatment. | — |
Contacts
Public ContactC. Heiden, van der
Ph.D., GZ-psycholoog-psychotherapeut, Hoofd Wetenschappelijk Onderzoek & Zorginnovatie PsyQ Rijnmond
Outcome results
None listed